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Analysis of the effects of depression associated polymorphisms
on the activity of the BICC1 promoter in amygdala neurones
S Davidson1, L Shanley1, P Cowie1, M Lear1, P McGufﬁn3, JP Quinn2, P Barrett4 and A MacKenzie1
The Bicaudal C Homolog 1 (BICC1) gene, which encodes an RNA binding protein, has been identiﬁed by genome wide association
studies (GWAS) as a candidate gene associated with major depressive disorder (MDD). We explored the hypothesis that MDD
associated single-nucleotide polymorphisms (SNPs) affected the ability of cis-regulatory elements within intron 3 of the BICC1 gene
to modulate the activity of the BICC1 promoter region. We initially established that the BICC1 promoter drove BICC1 mRNA
expression in amygdala, hippocampus and hypothalamus. Intriguingly, we provide evidence that MDD associated polymorphisms
alter the ability of the BICC1 promoter to respond to PKA signalling within amygdala neurones. Considering the known role of
amygdala PKA pathways in fear learning and mood these observations suggest a possible mechanism through which allelic
changes in the regulation of the BICC1 gene in amygdala neurones may contribute to mood disorders. Our ﬁndings also suggest
a novel direction for the identiﬁcation of novel drug targets and the design of future personalised therapeutics.
The Pharmacogenomics Journal (2016) 16, 366–374; doi:10.1038/tpj.2015.62; published online 6 October 2015
INTRODUCTION
Major depressive disorder (MDD) will affect up to 25% of the adult
population at some point in their lives1 and represents one of the
major causes of morbidity in the Western World2 with signiﬁcant
economic consequences.3 Although environmental factors such
as stress and inﬂammatory disease have a strong role in the
development of MDD,4,5 there is also signiﬁcant evidence of a
genetic contribution to susceptibility although estimates to the
scale of the contribution vary.6 To identify contributing genetic
loci we previously undertook a genome wide association (GWA)
analysis of 1346 individuals displaying recurrent depression
fulﬁlling DSM-IV or ICD-10 criteria of at least moderate severity
against 1288 unaffected individuals and identiﬁed a number of
candidate loci that were strongly associated with MDD (rs9416742,
P= 1.3 × 10− 7 and rs999845, P= 1.2 × 10− 7).7 Neither of these
single-nucleotide polymorphisms (SNPs) occurred within a gene
coding region or were found to be in linkage disequilibrium (LD)
with any coding SNP. However, both these loci occupied intron 3
of the Bicaudal C Homolog 1 gene (BICC1). BICC1 was originally
identiﬁed as mouse mutations which truncated the BICC1 protein
were shown to result in polycystic kidney disease in mice.8
Subsequent analyses showed that inactivation of BICC1 resulted in
Wnt9 and PKA10 pathway hyperactivation. Biochemical analysis
demonstrated that the BICC1 protein contained three K homology
domains that are involved in RNA binding and that BICC1 protein
is implicated in post-transcriptional regulation of gene expression
by antagonising miRNAs.11 More recent studies have also
implicated the involvement of BICC1 protein in modulating bone
density.12 Two mRNA isoforms have been reported for BICC1;
termed the long and the short isoform. Using microarray analysis
we detected the expression of the long isoform of BICC1 in
neuronal tissues but were unable to detect signiﬁcant levels of
expression of the short isoform.7 Interestingly, the long isoform
also displayed signiﬁcant evidence of differential expression
between different brain areas.7 Furthermore, MRI brain scan
studies of MDD patient’s demonstrated that the T allele of
rs999845, which was protective against MDD, was associated with
greater hippocampal volumes.13 Intriguingly, this effect was lost if
the patient had been exposed to stressful events during childhood
suggesting an epigenetic inﬂuence.13
The ﬁnding of disease associated SNPs within the intron 3 of the
BICC1 gene is consistent with the vast majority of other GWA
studies where 93% of disease associated SNPs fall within regions of
the genome that do not encode protein.14 The discovery that such
a high proportion of associated SNPs occur in non-coding regions
has hampered efforts to explore the functional consequences of
SNPs within the non-coding genome that still remains poorly
understood. Clues as to the functional consequences of many
disease associated SNPs come from whole genome functional
analyses as typiﬁed by the ENCODE consortium.15 Thus, 73% of
disease associated SNPs were detected in regions of the genome
that had characteristics of cis-regulatory regions determined using
techniques such as FAIRE-seq, DNAseI-seq and ChIP-seq that
identify regions of the genome that are less condensed or, which
bind transcription factors or speciﬁcally modiﬁed histones in vivo.14
These cis-regulatory sequences include promoters, enhancers and
silencer elements whose integrity is essential to maintaining
appropriate levels of the expression of speciﬁc genes, in speciﬁc
cells and in response to the correct stimuli.16 Indeed, the burden of
proof now suggests that polymorphic variation within these cis-
regulatory elements represents the main reservoir of heritable
disease including MDD.14
To determine the effects of non-coding SNPs on the tissue
speciﬁc activity of cis-regulatory elements we have previously
used a combination of comparative genomics, reporter assay
analysis in transgenic mice and magnetofected primary neurones.
In this way we have shown that cis-regulatory regions with strong
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cell speciﬁcity can be identiﬁed by virtue of their high degrees of
evolutionary conservation.17–21 Furthermore, we have demon-
strated that the activity and tissue speciﬁc characteristics of cis-
regulatory elements are dependent on the speciﬁc promoter used
and are best explored using endogenous promoter regions.20,21
We have also found that the functional consequences of allelic
variation only become signiﬁcant following the activation of
speciﬁc signalling pathways in speciﬁc cell types.22
On the basis of these previous studies we explored the hypo-
thesis that SNPs in LD with rs9416742 contributed to susceptibility
to MDD by altering the activity of highly conserved cis-regulatory
elements in intron 3 of the BICC1 gene on the cell speciﬁc and
inducible activity of the BICC1 promoter. We used a combination of
LD studies, comparative genomics, in situ hybridisation, transgenic
analysis and primary cell culture analysis to demonstrate the
presence of a novel polymorphic cis-regulatory element in LD with
rs9416742 that demonstrated signiﬁcant allele speciﬁc effects on
BICC1 promoter activity in primary amygdala neurones. The signiﬁ-
cance of these ﬁnding in health and in the complex underpinnings
of MDD are discussed.
MATERIALS AND METHODS
Bioinformatic analysis
Genomic analysis of the BICC1 locus was performed using the UCSC
genome browser (http://genome.ucsc.edu/). Allele frequency of SNPs was
determined using the NCBI SNP database (http://www.ncbi.nlm.nih.gov/
SNP/). Bioinformatic analysis of the effects of allelic variants on
transcription factor binding sites were determined using the RegSNP
website (http://viis.abdn.ac.uk/regsnp/Home.aspx).
PCR ampliﬁcation of regulatory regions, cloning- and site-directed
mutagenesis
Because of its high GC content BICCprom was ampliﬁed using
BICC1_Long_Prom_F and R oligonucleotide primers (Table 1) from human
placental DNA using a GC-rich PCR system (Roche, East Sussex, UK). BICC77
was ampliﬁed using ECR rs2393477_F and R oligonucleotide primers
(Table 1) from human placental DNA using the Expand High Fidelity PCR
system (Roche). PCR products were cloned into pGEM-T-easy (Promega,
Southamton, UK) and sequenced to conﬁrm PCR ﬁdelity and to determine
genotype. To reproduce both haplotypes of BICC77 site-directed mutagenesis
of BICC77 in pGEM-T Easy was undertaken using BICC1-SDM-61 primers
(forward and reverse) and BICC1-SDM-77 (forward and reverse; Table 1)
oligonucleotide primers using QuikChange II XL Site-Directed Mutagenesis
Kit (Agilent, Edinburgh, Scotland, UK).
DNA constructs
pBICCprom-LacZ. BICCprom was digested from pGEM-T easy using NcoI
and EcoICRI and ligated into the NcoI and SmaI sites of the SB LacZ
reporter plasmid (A kind gift from Sanbing Shen) to form pBICCprom-LacZ.
pBICCprom-Luc. BICCprom was digested from pGEMT-easy using NcoI and
SalI and ligated into the NcoI and XhoI sites of pGL4-23 (Promega).
pBICC77prom-Luc(CG and AA). BICC77 (CG or AA) was digested out of
pGEMT-easy using ZraI and SacI and placed in a ligation containing the
pGL4.23 vector linearised with NcoI and Sac1 and BICCprom digested from
pGEMT-easy using NcoI and EcoICRI.
Transgenic analysis (including lacZ stain)
Following linearization and removal of the plasmid backbone, BICCprom-
lacZ construct DNA was microinjected into one cell C57/BL6xCBA F1 mouse
embryos at a concentration of 2–4 ng μl− 1 as previously described.23
Surviving embryos were oviduct transferred into pseudopregnant CD1 host
mothers. Transgenic mice from each line were humanely sacriﬁced by lethal
injection of euthatol according to UK Home Ofﬁce guidelines. These mice
were then dissected to recover the brain which underwent submersion
ﬁxation in 4% PFA (paraformaldehyde disolved in phosphate buffered
saline) for 4 h. All tissues were then stained using 5-bromo-4-chloro-3-
indolyl-beta-D-galactopyranoside (X-gal) solution for 4–12 h as previously
described.23 X-gal stained tissues were then prepared for vibratome
sectioning by allowing tissue to equilibrate with increasing concentrations
of sucrose (to 30%) in phosphate buffered saline at 4 °C. Tissues were
equilibrated with bovine serum albumen/Gelatin solution (0.5 gelatin, 30
sucrose, 15.5% bovine serum albumen) overnight at 4 °C. Bovine serum
albumen/gelatin embedded tissue was then hardened by addition of one-
tenth of a volume of 25% gluteraldehyde. Fifty micron sections were then
cut on a Vibratome series 1000 (Leica, Milton Keynes, UK). Sections were
mounted on glass slides and photographed under light ﬁeld or phase
contrast illumination.
In situ hybridisation
Radioactive in situ hybridisation was carried out as previously described.24
Mouse cDNA for use as a template for the production of antisense BICC1
probe for radioactive in situ hybridisation was purchased from Source
Bioscience (Genbank accession no. AK076154.1).
Cell culture and luciferase reporter gene assays
Primary Amygdala cultures were prepared from P1-3 rat neonates as
described earlier.22 Cells were transfected with plasmid DNA using
Neuromag according to the manufacturer’s instructions (OZ Bioscience,
Marseilles, France). Brieﬂy, Neuromag reagent was added to a plasmid-media
preparation and incubated at room temperature for 15min allowing 250 ng
of plasmid DNA in the media per 150,000 cells to be transfected. The DNA-
Media-Neuromag solution was then added to previously prepared single cell
cultures in 24-well plates and incubated on a magnetic plate for 15min in a
cell culture incubator at 37 °C and 5% CO2. Luciferase activity of plasmid
constructs were measured using dual luciferase assay kits (Promega) using
lysates from cell cultures transfected with the GAL5.1 luciferase constructs.
Cell cultures were lysed and the proteins stabilized using the passive lysis
buffer as per the manufacturer’s instructions (Promega). The dual-luciferase
assay analysis was carried out on a Glomax 96-microplate luminometer
(Promega) using 20 μl of cell lysate per well of a white 96-well plate.
Data analysis
Sample sizes (n⩾ 3) were based on pooled amygdala neurones recovered
from at least three individual rat neonates. Statistical signiﬁcance of data
sets were analysed using either two way analysis of variance (ANOVA)
analysis with Bonferoni post hoc tests or using two tailed unpaired
parametric Student t-test as indicated using GraphPad PRISM version 5.02
(GraphPad Software, La Jolla, CA, USA).
Table 1. Names and sequences of oligonucleotides used in the construction of the plasmid reporter constructs described in the manuscript
Oligonucleotide Sequence (5’-3’)
BICC1_Long_Prom_F GTGGCAGTGTGTACGTGGTG
BICC1_Long_Prom_R AAAAGGAGTTAGAGGCTCAGTCG
ECR rs2393477_F TTCTTAGCCTTTCTGAAAATCAGTAG
ECR rs2393477_R TTAACTCTGTTTTCTGCCAGAGTGAG
BICC1-SDM-61 F GGAATATTATTTTTAACCTATCTAACGTATGGAGTTGACCCCCTAAAAG
BICC1-SDM-61 R CTTTTAGGGGGTCAACTCCATACGTTAGATAGGTTAAAAATAATATTCC
BICC1-SDM-77 F CATATTTCTCAAAGGTCCTATAAGCATTACAACACATTTATCAAAG
BICC1-SDM-77 R CTTTGATAAATGTGTTGTAATGCTTATAGGACCTTTGAGAAATATG
Abbreviation: BICC1, bicaudal C homolog 1.
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RESULTS
BICC1 displays spatially discrete mRNA expression within
components of the limbic system
Our previous GWA analysis provided a compelling case for
examining the involvement of allelic variations within intron 3 of
the BICC1 gene in major depressive disorder.7 We also provided
evidence that the long isoform of BICC1 (isoform 1), that includes
the ﬁrst seven exons (Figure 3a), showed strong differential
expression in speciﬁc nuclei of the human brain.7 In contrast, the
short isoform (isoform 2, lacks the ﬁrst 7 and last 3 exons),
although detectible in kidney and bone tissue, demonstrated
consistently low expression in all brain tissues.7 These observa-
tions argue against a role for the short isoform in brain function
and, for this reason, we concentrated our analysis on the long
isoform. Although our microarray analyses were highly informative
they lacked the resolution to determine the speciﬁc regions of the
brain that expressed BICC1. For this reason we used in situ
hybridisation using probes derived from the full length BICC1
complementary DNA that reﬂects the long isoform, on sections of
adult male mouse brain to determine whether BICC1 mRNA was
expressed throughout the brain or displayed discrete regions of
expression. These in situ analyses demonstrated that, although full
length BICC1 transcript expression was present in the majority of
tissues at low levels, areas of higher expression were evident
within discrete components of the limbic system including the
hippocampus, the hypothalamus and the amygdala (Figure 1).
There was also evidence of increased expression within the
cingulate cortex and the thalamus (Figure 1). Because the limbic
system plays a critical role in conditioned fear and mood
modulation these observations support a role for changes in the
expression of BICC1 long isoform in contributing to mood disorders.
Bioinformatic analysis of the BICC1 promoter
We have established that BICC1mRNA demonstrates tissue speciﬁc
expression patterns within regions of the mouse limbic system.
These ﬁndings are consistent with evidence of a role for SNP
variants within intron 3 of the BICC1 gene in MDD. Because these
SNPs are non-coding we next explored the hypothesis that they
inﬂuenced mood by altering the transcriptional regulation of BICC1
within the limbic system. However, we have no knowledge of the
systems regulating BICC1 mRNA expression within the brain. For
this reason we used information contained within the UCSC
genome browser to direct our studies and provide evidence of the
promoter regions supporting BICC1 expression in the brain. UCSC
describes the existence of two mRNA species transcribed and
spliced from the human BICC1 gene locus (Supplementary Figure
1A and Figure 3a). Thus, the short splice form is encoded by 10
exons distributed over 21 kb (GRCh37/hg19, chr10:60,553,182-
60,574,087) and the long splice form shares the same 10 exons but
has an additional 11 exons distributed over 318 kb (GRCh37/hg19,
chr10:60,272,942-60,591,445) (see Supplementary data Supple-
mentary Figure 1a.). Previous mRNA expression analysis of the
short and long splice-forms of BICC1 suggested that, although
expression of both splice-forms was detected in speciﬁc human
Figure 1. Autoradiographs of 10-μm coronal sections of adult male C57BL6 mouse midbrain (Bregma − 0.34 to − 2.70mm) hybridised to a S35
labelled BICC1 antisense RNA probe. amgd, amygdala; Cg, cingulate cortex; hip, hippocampus; hypo, hypothalamus; thal, thalamus.
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neuronal tissues and cells, the longer splice-form was expressed at
considerably higher levels and varied strongly between different
tissues suggesting that its expression is maintained by a stronger
promoter element.7 To conﬁrm this observation we used data
embedded in the ENCODE data set to explore the promoter
characteristic of DNA sequence around the transcriptional start
sites of the long and short splice-forms. Using accepted criteria
such as histone modiﬁcation patterns (H3K4me2, H3K4me3,
H3K9ac and H3K27ac) as well as FAIRE and DNAse1 hypersensi-
tivity patterns characteristic of promoter regions in a number of
different human cell lines (GM2878, HeLa, HepG2 and embryonic
stem cells etc.) we recovered data consistent with higher levels of
promoter activity around the transcriptional start site of the long
splice-form in comparison to the short isoform which demon-
strated fewer active promoter characteristics in all cell lines used
(Supplementary Figure 1b–e and Figure 3a) consistent with its
lower activity in microarray analysis reported by Lewis et al.7
Furthermore, the promoter of the long splice-form, was more
highly conserved outside of the coding region than the promoter
region of the short splice form (Supplementary Figure 2b and e).
Because of this evidence we focussed our subsequent efforts on
the promoter of the long splice form.
Cloning and characterisation of the BICC1 promoter
To isolate and characterise the long isoform promoter (henceforth
referred to as BICC1prom) we designed PCR primers (see Table 1)
to isolate a 691 bp region of the BICC1 locus that spanned both
the GC enriched region (75% GC content) and the region most
conserved in vertebrates (Supplementary Figure 2a). This
sequence also contained the ﬁrst exon of the long isoform of
BICC1. Following ampliﬁcation BICC1prom was cloned into a LacZ
reporter plasmid using an NcoI site that coincided with the
transcriptional start site of both BICC1 and the reporter LacZ gene
(Figure 2a). Using pronuclear microinjection and oviduct transfer
this reporter construct was used to generate a number of
transgenic mouse lines (n= 6). Brain tissues were recovered from
these lines and subjected to X-Gal staining. Two of the transgenic
mouse lines demonstrated robust and consistent staining for the
expression of the LacZ gene in areas of the cingulate cortex,
hippocampus, thalamus and in speciﬁc nuclei of the amygdala
including the basolateral, basomedial, central and lateral amyg-
daloid nuclei (Figures 2a–h). Because both lines produced similar
expression patterns in these areas it is highly unlikely that the
patterns of expression generated represented insertional effects
but were representative of BICC1prom activity. The activity of the
human BICC1prom within these components of the limbic
systems was entirely consistent with its role in supporting the
expression of mRNA that we describe above.
The BICC1 promoter is active in primary amygdala neurones
The analysis of BICC1prom in transgenic lines using a LacZ
reporter construct reﬂected the cell speciﬁc distribution of BICC1
mRNA in limbic regions of the brain (Figure 2). However, the
analysis of LacZ constructs using transgenic mice does not
represent an effective method of assaying the quantitative effects
of other regulatory regions, SNPs or activation of signal transduc-
tion pathways on BICC1prom. For this reason we cloned
BICC1prom into the NcoI site of a ﬁreﬂy luciferase plasmid
(pGL4.23; Promega) replacing the generic TATA box promoter to
form pBICC1prom-Luc (Figure 3b). Because of the role of the
amygdala in mood and fear behaviour we magnetofected
BICCprom-luc into cultured primary rat amygdala neurones
together with the renilla luciferase vector pGL4.74 and in parallel
with the pGL4.23 backbone plasmid. This demonstrated that the
BICC1 promoter was over 40 times more active in amygdala
derived neurones that the minimal TATA box promoter of the
pGL4.23 plasmid that was used as the basis of our luciferase
promoter constructs (Figure 3b). These observations further
support a role for the BICC1 promoter in the amygdala.
BICC1prom is moderately repressed by PKA activation but not PKC
activation
It is well established that modulation of the activity of protein
kinase A (PKA) pathways in the amygdala play a critical role in the
consolidation of fear memories.25,26 There is also evidence that
components of the protein kinase C (PKC) pathway are activated in
the amygdala during fear conditioning27 where they may also have
a role in fear learning.28,29 Due to the known involvement of PKA
and PKC pathways in fear memory and learning we explored the
effects of activation of these pathways on the activity of the BICC1
promoter in primary amygdala neurones. We found little evidence
that the PKC pathway could inﬂuence BICC1prom activity in
primary amygdala neurones (Figure 3c). We found some evidence
of negative regulation of BICCprom by activation of the PKA
pathway using forskolin but this was not statistically signiﬁcant
(Figure 3c).
Linkage disequilibrium analysis of rs9416742 and rs999845
We have provided evidence that BICC1prom is responsible for
supporting the discrete expression of BICC1 mRNA in the limbic
system. These studies provide a useful platform for further
exploring the possible effects of mood disorder associated allelic
variants in BICC1 intron 3 on the tissue speciﬁc activity of
BICC1prom. Using genome wide association studies we previously
demonstrated that a signiﬁcant association existed between the
rs9416742 and rs999845 polymorphisms (P=1.3× 10− 7 and
3.14× 10− 7, respectively) and susceptibility to MDD.7 As previously
mentioned neither of these SNPs occur within any coding regions
of the BICC1 gene nor were they in LD with coding SNPs. Because
evolutionary conservation has been shown to be highly suggestive
of functionality we explored the hypothesis that rs9416742 and
rs999845 occurred within conserved cis-regulatory regions. Unfor-
tunately, comparative genomics demonstrated that neither SNP
occurred within a region of the BICC1 locus which was highly
conserved or displayed markers indicative of cis-regulatory regions.
However, both SNPs were found to be in strong linkage
disequilibrium with a SNP (rs2393477) that occurred in a 200 base
pair region of human BICC1 intron 3 that had been highly
conserved in mammalian species as divergent from humans as
marsupials (opossum) and monotremes (platypus) (Figure 3a and
Supplementary Figure 3). This high degree of deep conservation
(‘depth’ refers to evolutionary time as opposed to degrees of
conservation by pairwise comparison) strongly suggests that this
sequence has an important biological function and has served in
maintaining species ﬁtness during the 210 million years since
placental mammals and monotremes diverged.30 This region of
homology was also 260 kb away from BICC1prom which is well within
the known range of inﬂuence of many cis-regulatory elements. Other
regions of BICC1 intron 3 between this cluster of SNPs were also
found to be highly conserved and also contained polymorphisms but
these were not found to be in signiﬁcant LD with either rs9416742 or
rs999845 (Figure 3a and Supplementary Figure 3).
BICC77 represses the activity of BICC1prom in amygdala neurones
in an allele speciﬁc manner
To determine whether allelic variants of highly conserved regions
of BICC1 intron 3 affected the activity of BICC1prom in amygdala
neurones we designed PCR primers (BICC77 for. and BICC77 rev.;
Table 1) to isolate a highly conserved 200 bp region of BICC1
intron 3 (BICC77) that contained rs2393477 and its close neighbour
rs10740761, which was in high LD (r240.95). BICC77 was then
subjected to two rounds of site-directed mutagenesis (SDM; see
Table 1 for SDM primers used) to recreate allelic variants of
MDD associated polymorphisms and the BICC1 promoter
S Davidson et al
369
© 2016 Macmillan Publishers Limited The Pharmacogenomics Journal (2016), 366 – 374
rs2393477 and its close neighbour rs10740761 and sequenced to
conﬁrm SDM ﬁdelity. Different BICC77 haplotypes were cloned
into BICCprom-luc to form pBICC77AA-Luc and pBICC77CG-Luc
(Figure 3a). Magnetofection of these constructs into primary
amygdala cells demonstrated that BICC77 strongly repressed
BICC1 promoter activity in these cells. Interestingly, BICC77AA
had a signiﬁcantly stronger repressive effect that did BICC77GC
(Figures 3a and 4a).
BICC177 further represses BICC1prom activity following PKA but
not PKC activation.
We have shown that allelic variants of the highly conserved
sequence BICC77 are able to differentially down regulate the
activity of BICC1prom within primary amygdala neurones. Because
of the essential role played by cis-regulatory elements in relaying
signal transduction information to promoter regions22 we next
explored the possibility that allelic variants of BICC77 differed in
their ability to relay signal transduction signals to BICC1prom. We
treated primary amygdala cultures transfected with allelic variants
of pBICC77prom-Luc (AA and CG) with forskolin or PMA. PMA had
no signiﬁcant effect on the activity of either allelic variant and
forskolin did not signiﬁcantly alter the ability of BICC77GC to repress
BICC1prom activity (Figure 4b). However, BICC77AA demonstrated
signiﬁcantly higher repression of BICC1prom activity following
treatment with the PKA agonist forskolin (Figures 3a and 4b).
Bionformatic analysis of transcription factor binding at rs2393477
and rs10740761.
We asked whether it was possible to use a bioinformatics
approach to identify candidate transcription factors whose
binding to BICC77 was allele dependent. We used the RegSNP
website to determine whether the AA haplotype altered the
predicted binding efﬁciency of known transcription factors
compared with the protective GC haplotype. Examination of
rs10740761 using RegSNP shows that the C allele potentially binds
the transcription factor Deaf1 which is suspected in causing
Figure 2. (a). Diagrammatic representation of the BICC1prom-LacZ reporter constructs (not to scale). (b-h) photomicrographs of coronal
sections of mouse midbrain transgenic for the BICC1prom-LacZ plasmid and stained with X-Gal to detect the expression of LacZ from the
transgene in the hippocampus (b), the cingulate cortex (c), the hypothalamus (d) and the amygdala (e-h). BLA, basolateral amygdaloid
nucleus; BMA; basomedial amydaloid nucleus; LacZ, β-galactosidase gene; CA1-CA3, CA regions of hippocampuscc, corpus colosum; CeA;
central amygdaloid nucleus; Cg, cingulate cortex; DG, dentate gyrus; DM, dorsomedial hypothalamic nucleus; MeA, medial amygdaloid
nucleus; mt, mammillothalamic tract; VMH, ventromedial hypothalamic nucleus; PH, posterior hypothalamic area; VMH, ventromedial
hypothalamic nucleus.
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memory deﬁcits and anxiety like behaviour if deleted from the
mouse genome.31 The C allele of rs10740761 was predicted to bind
Deaf 1 with a matrix score of 0.7323 wheras the A allele only had a
matrix of 0.5. The A allele of rs2393477 was predicted to bind GATA
factors (1, 2, 3 and 6) with much higher afﬁnity (matrix score for C
allele = 0.7 and for T allele 0.92). This is intriguing as overexpression
of GATA factors has been associated with depressive behaviour32
and a highly conserved C/EBP binding site exists just next to this
locus. This arrangement of transcription factor binding has been
associated with PKA activation on the past.33
DISCUSSION
To locate the presence of a human genomic locus that could
contribute to susceptibility to major depressive disorder we
carried out a GWA analysis of a large patient cohort and
succeeded in identifying two SNPs within intron 3 of the BICC1
gene with signiﬁcant association. We observed that the T allele of
the most strongly associated SNP; rs9416742, that has a frequency
of 0.235 in healthy individuals, was found to have a protective
affect against depression. Although neither of these SNPs were
Figure 3. (a) A diagrammatic representation (not to scale) of the BICC1 locus demonstrating the linear relationships between the genomic
locus (black line) and the short (light blue lines) and long (dark blue lines) mRNA isoforms. Exons are indicated by heavy vertical lines. Long
and short isoform promoters are indicated using bent black arrows. The BICC1 promoter and BICC77 are represented by a red ﬁlled box and a
blue ﬁlled box respectively and represents a distance of 260 kb. Sites of MDD associated SNPs are represented by thin red vertical lines and
conserved SNPs in strong linkage disequilibrium are indicated by thin black vertical lines. The region of the BICC1 locus in strong LD is
represented by a red triangle. The functional relationships suggested in the current manuscript are summarised using broken red lines to
indicate the increased repressive effects of BICC77AA on BICC1prom compared with BICC77GC in primary amygdala neurones. (b)
diagrammatic representation of the luciferase reporter constructs used in subsequent experiments. (c) A bar graph representing the results of
a dual-luciferase analysis comparing the activity of the pBICCprom-Luc vector (BICCprom) to that of pGL4.23 following magnetotransfection
into primary amygdala neurones. (d) Effects of treatment of primary amygdala neurones magnetofected with the pBICCprom-Luc plasmid and
treated with 10 μM forskolin or 10 μM PMA for 16 h before dual-luciferase analysis. n= 15. MDD, major depressive disorder; N.S., not signiﬁcant;
PMA, phorbol 12-myristate 13-acetate; SNP, single-nucleotide polymorphism. Error bars are standard error of the mean, n= 4, analysis using
(c) two tailed unpaired t-test or (d) ANOVA. n.s. not signiﬁcant, ***Po0.005.
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found within the coding region of BICC1, or within an area of
intron 3 that could be identiﬁed as a cis-regulatory region, they
were found to be in strong linkage disequilibrium with a SNP
within a region of intron 3 that had been conserved for 210
million years thus representing the majority of the extent of
mammalian evolution. We isolated this conserved region, that we
called BICC77, and reproduced both of the allelic forms present in
the human population (referred to as AA and GC). Because these
SNPs lay within the BICC1 gene and because subsequent analysis
had demonstrated that the allelic variants of BICC1 in question
were associated with greater hippocampal volumes13 we tested
the hypothesis that allelic variants of BICC77 differentially
regulating the transcription of the BICC1 gene in the brain.
To test this hypothesis it was necessary to ﬁrst determine
whether BICC1 was expressed in any areas of the brain known to
control mood. We used in situ hybridisation to demonstrate that
BICC1 mRNA was more strongly expressed in speciﬁc areas of the
limbic system including the hippocampus, amygdala and
hypothalamus. Subsequent analysis of existing genomic databases
succeeded in identifying the active BICC1 promoter by virtue of its
extent of conservation, its accessibility to FAIRE and DNAseI
analysis and its interaction with known promoter histone marks.
Using magnetofection of primary amygdala cells with luciferase
markers and dual-luciferase assays we were able to show that this
promoter region was highly active in primary amygdala neurones
compared with a generic TATA box promoter. Furthermore, by
generating two different lines of transgenic mice with the BICC1
promoter linked to the LacZ gene we also demonstrated
pronounced tissue speciﬁcity in the activity of the BICC1 promoter
in hippocampus, amygdala and hypothalamus. These analyses
established the expression of BICC1 and the activity of its
promoter in regions of the limbic system that have critical roles
roles in mood modulation and depressive behaviour. In addition,
identifying the tissue speciﬁc activity of the BICC1 promoter
provided us with a useful platform for studying the effects of
allelic variants of BICC77 on its activity and hence the activity of
the BICC1 gene.
We next asked what effect BICC77 would have on the activity of
the BICC1 promoter in primary amygdala neurones and we were
able to demonstrate that BICC77 acted as a strong repressor of
BICC1 promoter activity within these cells. We have previously
observed this model in the regulation of BDNF promoter 4
whereby a highly conserved region of the BDNF locus, containing
a SNP associated with depression (BE5.2), caused signiﬁcant
repression of BDNF promoter 4 within 3 different primary cell
types (hippocampus, cortex and amygdala).22 These analyses of
the BDNF locus suggested an important role for selective negative
regulation in the modulation of inducible gene expression in the
brain. In combination with this previous study, the current study
highlights the complexities of understanding the speciﬁc mechan-
isms by which depression associated allelic variants may alter
pathological susceptibility. Thus, by subtly changing the delicate
homoeostatic balance of negative and positive regulatory
mechanisms required to maintain levels of gene expression
essential for mental health differences in the activity or regulatory
elements over a life time, or following trauma, may be sufﬁcient to
contribute to mental illness. There is every reason to believe that
identifying the effects of allelic variation on negative regulation
will be critical for understanding the causes of psychiatric
pathologies including depression.
With this concept in mind we then asked whether allelic
variants of BICC77 differed in their ability to negatively regulate
the activity of the BICC1 promoter in amygdala cells. We recreated
the different genotypes of BICC77 present in the human
population (AA and CG) and found that the minor haplotype of
BICC77(GC), that is in LD with the protective T allele of rs9416742,
was not as potent a repressor as the major allele (AA). Whilst there
is currently no evidence to suggest that levels of BICC1 expression
within individuals with the CG haplotype of BICC77 are higher
than those with the AA haplotype, the observation of a signiﬁcant
difference in the inﬂuence of these haplotypes on the activity of
the BICC1 promoter in primary amygdala neurones provides us
with a possible insight into a mechanism contributing to mood
disorders. These observations reﬂect the results of a previous
study, which demonstrated that the CA haplotype of the GAL5.1
enhancer, that supports expression of the galanin neuropeptide in
areas of the brain including the paraventricular nucleus and
amygdala, was signiﬁcantly weaker than the GG haplotype in
primary hypothalamic neurones.19 Subsequent analysis of these
haplotypes in human cohorts suggested that the CA haplotype
was protective against alcohol and cannabis abuse in certain
populations34,35
Figure 4. (a) Bar graphs showing the results of dual-luciferase analysis on primary amygdala neurones magnetofected with pBICC1prom-Luc
(BICC1prom), pBICC77GCprom-Luc (BICC77GC) or pBICC77AAprom-Luc (BICC77AA) (n= 9). (b) The results of dual-luciferase analysis of primary
amygdala neurones magnetofected with either the pBICC77GCprom-Luc (BICC77GC) or pBICC77AAprom-Luc (BICC77AA) and treated with
DMSO, forskolin (For) or PMA. All plasmids were co-transfected with the pGL4.74 renilla luciferase plasmid (n= 10). **Po0.01. Error bars
represent the standard error of the mean. All analysis in Figure 4 undertaken using two way ANOVA with Bonferroni post hoc tests. ANOVA,
analysis of variance; DMSO, dimethyl sulfoxide; N.S., not signiﬁcant; PMA, phorbol 12-myristate 13-acetate.
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It is accepted that one of the main roles of gene regulatory
regions is to interpret signal transduction information within the
surrounding cell cytoplasm for the transcriptional machinery (RNA
polymerase TFIID and mediator) bound at the promoter region of
genes. In the speciﬁc case of the amygdala, a number of signal
transduction pathways have been implicated in modulating the
cellular systems that control mood.36 One of the best studied is
the PKA signal transduction pathway that is activated in amygdala
neurones by binding of stress released epinephrine to B1
adrenergic receptors.36 Because of the known contribution of
chronic stress in the exacerbation of mood disorders we sought to
determine the effects of agonists of signal transduction pathways
such as PKA and PKC known to have a role in amygdala function.
Treatment of transfected cultures to activate the PKC pathway had
no effect on BICC77 and no allelic differences were observed.
Activation of PKA pathways in transfected cells also had little or no
effect on the ability of the BICC77GC haplotype to repress the
BICC1 promoter. Intriguingly, however, forskolin treatment
resulted in further repression of the BICC1 promoter by BICC77AA.
Further bioinformatic analysis suggested that the AA haplotype
had an increased afﬁnity with a combination of transcription
factors (GATA and C/EBP) that have previously been associated
with PKA response.33 Because the AA haplotype of BICC77 is the
major haplotype within the human population and also represents
the ancestral haplotype present in all other mammals, it can be
hypothesised that the CG allele of BICC77, which is in LD with the
protective T allele of rs9416742, is not only less repressive of BICC1
promoter activity but has also lost its ability to respond to
activation by PKA modulated signalling inputs. Indeed, it could be
hypothesised that the reduction in its ability to repress the BICC1
promoter or to respond to PKA signalling may be mechanistically
related to the protective effects observed for the T allele of
rs9416742.
CONCLUSION
Major depressive disorder has been shown to be a highly complex
disease state to diagnose and this may reﬂect the large numbers
of unreplicated genome wide association studies hits associated
with this condition (4100; HuGE genome navigator). There is also
increasing evidence of the possibility of masking or exacerbation
of depression phenotypes through epigenetic inﬂuences that are
altered following early life traumatic events that may have a role
in reducing the efﬁcacy of genetic association analysis.37,38
However, the overwhelming conclusion that has been drawn
from the results of these studies is that the genetic and epigenetic
inﬂuences in susceptibility to mood disorders are unlikely to be
solely due to changes in gene coding regions but will instead
affect the mechanisms that control the spatial, tissue speciﬁc and
inducibility of these genes. The current manuscript describes the
use of novel combinations of different techniques to determine
the mechanisms through which alleles associated with MDD
might contribute to susceptibility. Thus, in addition to suggesting
a novel contributory mechanism towards MDD susceptibility the
current manuscript describes innovative approaches to exploring
the mechanisms through which non-coding disease associated
SNPs may contribute to disease.
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